Successful treatment of pyrotinib for bone marrow metastasis induced pancytopenia in a patient with non‐small‐cell lung cancer and ERBB2 mutation

ERBB2 mutations are found in about 2% of patients with non‐small cell lung cancer (NSCLC). A recent study reported that pyrotinib (an irreversible pan ErbB inhibitor) had superior antitumor effect compared to other tyrosine kinase inhibitor therapies in patients with ERBB2 mutations. Bone marrow met...

Full description

Saved in:
Bibliographic Details
Published in:Thorac Cancer
Main Authors: Wu, Yanyan, Ni, Jun, Chang, Xiaoyan, Zhang, Xiaotong, Zhang, Li
Format: Artigo
Language:Inglês
Published: John Wiley & Sons Australia, Ltd 2020
Subjects:
Case Reports
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7327666/
https://ncbi.nlm.nih.gov/pubmed/32458584
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13480
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items